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Abstract: The Sonogashira cross-coupling, a key step in the syntheses of the mGlu5 antagonists
MMPEP and MTEP, provided an improved three-step method for the preparation of MMPEP in
62% overall yield. Using Spartan molecular modeling kit an explanation for the failure to employ
analogues method in the synthesis of MTEP was sought. The DFT calculations indicated that
meaningful isolated yields were obtained when the HOMO energy of the aryl halide was lower than
the HOMO energy of the respective alkyne.
Keywords: Sonogashira cross-coupling; MMPEP; MTEP; mGlu5 antagonist
1. Introduction
Metabotropic glutamate receptor subtype 5 (mGlu5) [1–3] is a 7-member transmembrane
G-protein coupled receptor, which based on its pharmacology belongs to the group I of
metabotropic receptors and regulates glutamate, a major neurotransmitter in the mammalian
brain. Consequently, mGlu5 is associated with numerous central nervous system (CNS) disorders
such as Parkinson’s [1,4] and Alzheimer’s [5,6] disease. For this reason mGlu5 has been studied
extensively as a potential therapeutic target [7], resulting in the identification of 2-methyl-
6-(phenylethynyl)pyridine (MPEP, 1, Figure 1) [8,9] as a potent mGlu5 antagonist which presented
the basis for further Structure Activity Relationship (SAR) studies. Additionally, significant
efforts have been made in establishing positron emission tomography (PET) [10] radiotracers for
non-invasive imaging of mGlu5 [11] with the aim of further assisting drug development and
also as a potential diagnostic tools of CNS impairments. As a part of the on-going program
on the development of fluorine-18 labelled mGlu5 radiotracer based on the structural scaffold of
(E)-3-[(6-methylpyridin-2-yl)ethynyl]cyclohex-2-enone O-[11C]methyl oxime ([11C]-ABP688) [12,13]
we recently required the two mGlu5 antagonists 2-((3-methoxy-phenyl)ethynyl)-6-methylpyridine
(MMPEP, 2) [14] and 2-methyl-4-(pyridine-3-ylethynyl)thiazole (MTEP, 3, Figure 1) [15–17]. The key
transformation in the syntheses of both mGlu5 antagonists was a Sonogashira cross-coupling [18].
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Figure 1. Structures of MPEP (1), MMPEP (2) and MTEP (3) and their assembly via the Sonogashira 
cross-coupling. 
The Sonogashira cross-coupling reaction has been used for other analogous molecules [19,20] 
and is characterized by the ease of synthetic manipulation required to perform the reaction, 
generally mild reaction conditions, including ambient temperature and relatively short reaction 
times, and the versatility of substrates amenable to these conditions [21]. Extensive studies on the 
mechanism of the Sonogashira cross-coupling allowed for postulations about the effect of 
electronegativity of coupling partners, where electron-donating substituents on the aryl or alkyl 
halide lead to a higher activation barrier and electron-withdrawing substituents on the aryl or alkyl 
halide lower the barrier [22]. It was hypothesized that turnover-determining step in which aryl 
halides participate is preceded by the end-on ligation of the halogen atom to palladium making it 
therefore an electron-donating step [21]. Thus, electron-donating groups with higher HOMO energy 
of the substrate form more stable complexes and as a consequence have higher rate determining 
activation barrier. On the other hand, electron-withdrawing groups with low HOMO energy, hence 
lower the activation barrier and facilitate oxidative insertion. Herein we report our findings about 
the application of the Sonogashira coupling in the syntheses of two mGlu5 antagonists resulting in a 
shorter synthetic route to MMPEP than that previously described. Rationale for the reactivity of 
Sonogashira partners was found through HOMO energy calculations using Density Functional 
Theory (DFT). 
2. Results and Discussion 
The previously reported synthesis of MMPEP involved a four step route starting with 
commercially available bromide 4 (Scheme 1) and giving 31% overall yield [14]. In the first step, 4 
was converted to alkyne 12 employing Sonogashira cross-coupling, and the trimethylsilyl 
functionality was then removed under basic conditions (compound 6) and the trimethyltin group 
introduced onto the terminal alkyne in 13, and 13 then reacted with aryl bromide 7A under Stille 
cross-coupling reaction conditions to afford MMPEP (2). Due to the total number of transformations 
as well as the toxicity of tin, an alternative direct route to access 2 was sought. Use of the same 
bromide 7A with either TMS alkyne 12 in the presence of TBAF·THF for in situ deprotection, or the 
deprotected equivalent 6, formed in one step from 2-bromopyridine (see Supplementary Materials), 
failed to furnish MMPEP (Scheme 1). The latter had precedent in the synthesis of ABP688 [23]. In this 
case, 3-bromocyclohex-2-enone was coupled with 6 in 60% yield but the reaction mixture required 
heating to 55 °C (not shown). 
Figure 1. Structures of MPEP (1), MMPEP (2) and MTEP (3) and their assembly via the
Sonogashira cross-coupling.
The Sonogashira cross-coupling reaction has been used for other analogous molecules [19,20]
and is characterized by the ease of synthetic manipulation required to perform the reaction, generally
mild reaction conditions, including ambient temperature and relatively short reaction times, and the
versatility of substrates amenable to these conditions [21]. Extensive studies on the mechanism of the
Sonogashira cross-coupling allowed for postulations about the effect of electronegativity of coupling
partners, where electron-donating substituents on the aryl or alkyl halide lead to a higher activation
barrier and electron-withdrawing substituents on the aryl or alkyl halide lower the barrier [22].
It was hypothesized that turnover-determining step in which aryl halides participate is preceded
by the end-on ligation of the halogen atom to palladium making it therefore an electron-donating
step [21]. Thus, electron-donating groups with higher HOMO energy of the substrate form more stable
complexes and as a consequence have higher rate determining activation barrier. On the other hand,
electron-withdrawing groups with low HOMO energy, hence lower the activation barrier and facilitate
oxidative insertion. Herein we report our findings about the application of the Sonogashira coupling
in the syntheses of two mGlu5 antagonists resulting in a shorter synthetic route to MMPEP than that
previously described. Rationale for the reactivity of Sonogashira partners was found through HOMO
energy calculations using Density Functional Theory (DFT).
2. Results and Discussion
The previously reported synthesis of MMPEP involved a four step route starting with
commercially available bromide 4 (Scheme 1) and giving 31% overall yield [14]. In the first step, 4 was
converted to alkyne 12 employing Sonogashira cross-coupling, and the trimethylsilyl functionality was
then removed under basic conditions (compound 6) and the trimethyltin group introduced onto the
terminal alkyne in 13, and 13 then reacted with aryl bromide 7A under Stille cross-coupling reaction
conditions to afford MMPEP (2). Due to the total number of transformations as well as the toxicity of
tin, an alternative direct route to access 2 was sought. Use of the same bromide 7A with either TMS
alkyne 12 in the presence of TBAF·THF for in situ deprotection, or the deprotected equivalent 6, formed
in one step from 2-bromopyridine (see Supplementary Materials), failed to furnish MMPEP (Scheme 1).
The latter had precedent in the synthesis of ABP688 [23]. In this case, 3-bromocyclohex-2-enone was
coupled with 6 in 60% yield but the reaction mixture required heating to 55 ◦C (not shown).
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Scheme 1. 1-Bromo-3-methoxybenezene (7A) as reacting partner in Sonogashira coupling to access 
MMPEP (2). 
The failure to form the desired cross-coupling product between bromide 7A and alkynes 12 or 6 
prompted us to further explore an alternative synthetic route towards 2 (Scheme 2). For this, alkyne 
5A was obtained from 3-methoxyanisole (14) in two steps employing classical Corey-Fuchs reaction 
in 66% overall yield. [15] When alkyne 5A was reacted directly with 2-bromo-6-methylpyridine (4) 
under Sonogashira cross-coupling conditions at ambient temperature, MMPEP (2) was isolated in 
93% yield (Scheme 2). This demonstrated that Stille coupling was not required and that 2 can be 
prepared in excellent yield of 62% over only three reaction steps and on 1 g scale. 
 
Scheme 2. Improved three step synthesis of MMPEP (2) with 1-ethynyl-3-methoxybenzene (5A). 
We next sought to explore an analogous synthetic strategy for the construction of MTEP (3). 
Our recent report on the synthesis and properties of novel ABP688 derivative (16, ThioABP) [24] 
established the successful application of Sonogashira cross-coupling between 
4-bromo-2-methylthiazole (8) and alkyne 15 at ambient temperature in moderate 40% yield (Figure 
2). The same bromide 8 in reaction with 3-ethynylpyridine (9), however, afforded desired product in 
only 8% conversion, based on the NMR analysis of isolated mixtures (Figure 2, entry 1). Analogue 3 
could not be separated from the major product of the reaction, which was presumed to be result of 
self-coupling of alkyne 9 but remained uncharacterized. When reaction was repeated under the 
same conditions, it failed to yield any of the desired 3, thus proving to be non-reproducible and an 
inefficient way to obtain 3. At elevated temperature, reaction of bromide 8 with akyne 9 also failed to 
yield desired 3 (Figure 2, entry 2). Furthermore, the reaction was unsuccessful with silylated alkyne 
17, which was desilylated with TBAF·THF in situ (Figure 2, entry 3) therefore excluding the 
possibility of effects of presence of TBAF·THF in the reaction mixture on reactivity of coupling 
partners. The possibility of TBAF·THF effect on the success of Sonogashira cross-coupling was 
founded based on our previously published observations whereby in situ desilylated 
α-fluoroalkynes using TBAF·THF were successfully coupled to bromopyridines under analogous 
reaction conditions (see Figure 3, alkyne 22) [25].  
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Scheme 1. 1-Bromo-3-methoxybenezene (7A) as reacting partner in Sonogashira coupling to access
MMPEP (2).
The failure t o m th desired cross-coupling product bet een bromide 7A and alkynes 12 or 6
prompted us o further explore an lternative synthetic route t wards 2 (Schem 2). For this, alkyne
5A was obtained from 3-methoxy nisole (14) in two steps mploying classical Core -Fuchs reaction
in 66% overall yield [15]. When alkyne 5A was reacted directly with 2-bromo-6-methylpyridine (4)
under Sonogashira cross-coupling conditions at ambient temperature, MMPEP (2) was isolated in 93%
yield (Scheme 2). This demonstrated that Stille coupling was not required and that 2 can be prepared
in excellent yield of 62% over only three reaction steps and on 1 g scale.
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Scheme 2. Improved three step synthesis of MMPEP (2) with 1-ethynyl-3-methoxybenzene (5A).
We next sought t explore an analogous synthetic strategy for the construction of MTE (3). Our
recent report on the synthesis and properties of ovel ABP688 derivative (16, ThioABP) [24] established
the successful applicat on of Sonogashira cross-coupling between 4-bromo-2-methylthiazole (8) and
alkyne 15 at am ient temperature in moderate 40% yield (Figure 2). The same bromi e 8 in reaction
with 3-ethynylpyridine (9), however, afforded desired product in only 8% conversion, bas d on the
NMR analysis f isolated mixtures (Figure 2, entry 1). Analogue 3 could not be separ ted from
the major produc of the reac ion, which was p sumed t be result of self-coupling of alkyne 9
but remained uncharacterized. When reaction was repeated under the same conditions, it failed to
yield any of the desired 3, thus proving to be non-reproducible and an inefficient way to obtain 3.
At elevated temperature, reaction of bromide 8 with akyne 9 also failed to yield desired 3 (Figure 2,
entry 2). Furthermore, the reaction was unsuccessful with silylated alkyne 17, which was desilylated
with TBAF·THF in situ (Figure 2, entry 3) therefore excluding the possibility of effects of presence of
TBAF·THF in the reaction mixture n reactivity of coupling partners. The possib lity of TBAF·THF
effect on the succ ss of Sonogashira cross-coupling was founded based on our previously publi hed
observati s whereby in situ desilylated α-fluoroalkynes using TBAF·THF were successfully coupled
to bromopyridines under analogous reaction conditions (see Figure 3, alkyne 22) [25].
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Figure 2 4-Bromo-2-methylthiazole (8) as a reacting partner in Sonogashira coupling en route to 
MTEP (3). 
The literature report of the synthesis of MTEP (3) is analogous to the one depicted in Scheme 3. 
Silylated alkyne 20 was prepared in two steps starting from commercially available acid chloride 18 
with 76% overall yield. The Sonogashira cross-coupling between 20 and 11 was performed at 60 °C, 
in the presence of TBAF·THF which was added via syringe pump over several hours [15]. In our 
hands, this protocol afforded 52% of 3 (entry 1).  
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(10 or 20) as coupling partners. 
Figure 2. 4-Bromo-2-methylthia cting partner in Sonogashira coupling en route to
MTEP (3).
Our findings suggested that both reacting partners play a significant role in the cross-coupling and
are determinants in the reaction success, which lead us to conduct a comparison with the previously
reported synthesis of 3.
The literature report of the synthesis of MTEP (3) is analogous to the one depicted in Scheme 3.
Silylated alkyne 20 was prepared in two steps starting from commercially available acid chloride 18
with 76% overall yield. The Sonogashira cross-coupling between 20 and 11 was performed at 60 ◦C,
in the presence of TBAF·THF which was added via syringe pump over several hours [15]. In our
hands, this protocol afforded 52% of 3 (entry 1).
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Our synthesis thus compared favourably to the one previously published with 39% overall yield
vs. 25% reported over the same number of steps. Using the same reacting partners the reaction
was then performed at ambient temperature and TBAF·THF was added in one portion (entry 2,
an approach previously applied successfully for the series of α-fluorinated oximes with pyridinyl
bromides) [25] but this failed to give the desired coupling product in a meaningful amounts. Alkyne 20
was then desilylated to give 10 prior to its addition to the reaction mixture and attempted Sonogashira
cross-coupling at ambient temperature gave only trace amounts of desired product (entry 3). To further
confirm effects TBAF·THF may have 10 was prepared either as neat material when desilylation was
perfomed with KOH as a base, or as a crude mixture containing TBAF·THF when desilylation was
done using TBAF solution. Interestingly, either attempt afforded only trace (<1%) amounts of desired
product (see Supplementary Materials). With these results in hand we aimed to assess possible reason
for different reactivity of the same bromide (e.g., reaction of 8 with 15 and 9 or 17). Considering the
electronegativity of the halides as an important factor [21,22] an explanation was sought through
calculation of the respective HOMO energies.
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Figure 3. Difference in values of HOMO energies of reacting partners (∆EHOMO) calculated
using DFT method compared to experimental yields. Note: “—” indicates that reaction was not
performed experimentally.
Equilibrium as well as HOMO and LUMO energies were calculated using the DFT method
within the Spartan Molecular Modeling kit (the values are provided in the Supplementary Materials).
The DFT method as well as the basis set used has previously been applied successfully for other
computational studies on the mechanism of Sonogashira coupling [22]. The HOMO energies were
calculated for both reacting partners, the halide and the alkyne. As discussed in the Introduction, it
has been reported that the lower the HOMO energy of the halide, the more facile oxidative insertion of
Pharmaceuticals 2018, 11, 24 6 of 13
the palladium into the aryl-halide bond (i.e., more facile interaction between HOMO of the halide and
the respective a1 acceptor orbital on the metal). However, our experimental data showed different
reactivity of the same aryl halides, thus suggesting that HOMO energy of the aryl halide is not the only
determinant of the reaction success. For this reason, HOMO energies of halides and reacting alkynes
were compared with respect to the experimentally obtained yields and the difference in HOMO values
between the two (∆EHOMO = EHOMO (halide) − EHOMO (alkyne)) is provided in Figure 3. It was
found that product formation was not guaranteed if halide reacted with the alkyne which HOMO
energies were of the same value or higher. Meaningful yields of desired products up to 93% were
obtained when the HOMO energy of halide was lower than the HOMO energy of the reacting alkyne.
In mechanistic terms, oxidative insertion of palladium to halide will proceed at the same rate for
halides of equal HOMO energies, and the reaction outcome is further determined by the co-ordination
of alkyne to copper(I). While the oxidative insertion of palladium (i.e., first catalytic cycle) is studied
and well understood, the subsequent catalytic cycle (i.e., transmetalation) is poorly known and some
studies [21] show the possibility of tandem palladium/cooper catalysis. Considering the possibility
that both metals can react, and to facilitate oxidative addition, our findings suggest that the product
formation is dependent on the HOMO energy of both coupling partners. Although only a subset of
reacting possibilities for given halides and alkynes of interest was explored experimentally, in those
cases the isolated yields were in agreement with the computationally based hypothesis. Furthermore,
results in Figure 3 indicate that cyclic aliphatic alkynes outperform heterocyclic alkynes in terms of
reactivity in Sonogashira coupling reactions thus showcasing importance of electronic nature of alkyne
coupling partners.
Furthermore, for the explored halides and alkynes HOMOs were different not only in terms of
their respective energies, but their nature too. For example for alkynes 5A, 6 and 9 HOMOs were
centered on the aromatic ring unlike 10 in which HOMO was centered on the alkyne. While HOMO
of oxime 15 was distributed across the conjugated system of alkyne, cyclic alkene and N-oxime (see
Supplementary Materials), oxime 22 had HOMO centered on the N-oxime functionality only (Figure 4).  
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Similarly, for two of the bromides (4 and 21) HOMO was centered on the carbon bearing bromide,
whereas HOMO was centered in the position para to the bromide-bearing carbon for bromides 11,
7A and 8, thus suggesting that the nature of HOMO varied significantly amongst the investigated
alkynes/halides. For this reason, HOMO energy alone may not be sufficient indicator of the complex
nature of reactive species in the Sonogashira cross-coupling reaction; however our computational
findings have allowed explanation for the experimental results observed in the syntheses of MMPEP
and MTEP.
3. Materials and Methods
3.1. General Techniques
All reactions requiring anhydrous conditions were conducted in flame-dried glass apparatus
under an atmosphere of inert gas. All chemicals and anhydrous solvents were purchased from Aldrich
(St. Gallen, Switzerland) or ABCR (Karlsruhe, Germany) and used as received, unless otherwise
noted. Reported density values are for ambient temperature. Preparative chromatographic separations
were performed on Aldrich Science silica gel 60 (35–75 µm) and reactions followed by TLC analysis
using Sigma-Aldrich (St. Gallen, Switzerland) silica gel 60 plates (2–25 µm) with fluorescent indicator
(254 nm) and visualized with UV or potassium permanganate. 1H- and 13C-NMR spectra were
recorded in Fourier transform mode at the field strength specified on Avance FT-NMR spectrometers
(Bruker, Faellanden, Switzerland). Spectra were obtained from the specified deuterated solvents in
5 mm diameter tubes. Chemical shift in ppm is quoted relative to residual solvent signals calibrated
as follows: CDCl3 δH (CHCl3) = 7.26 ppm, δC = 77.2 ppm. Multiplicities in the 1H-NMR spectra are
described as: s = singlet, d = doublet, t = triplet, q = quartet, quint. = quintet, m = multiplet, b = broad;
coupling constants are reported in Hz.
3.2. Syntheses
1-Ethynyl-3-methoxybenzene (5A). A one-necked round bottom flask was charged with
triphenylphosphine (10.5 g, 40 mmol, 4 eq.), then carbon tetrabromide (6.63 g, 20 mmol, 2 eq.) and
the yellow solid mixture was carefully dissolved in anhydrous dichloromethane (36 mL; CAUTION:
vigorous reaction!) and the resulting orange mixture was allowed to cool to 0 ◦C (the ice bath). The
heterogeneous and red in colour mixture was allowed to stir and then treated with m-anisaldehyde
(1.2 mL, 1.36 g, 10 mmol, 1 eq., d = 1.119) dropwise over 1 min and the resulting dark orange mixture
was allowed to stir at 0 ◦C for 30 min and then the cooling bath was removed and stirring continued
at ambient temperature for 38 min. After this time the crude mixture was quenched with ice cold
H2O (40 mL) and diluted with hexanes (25 mL) and the two layers were well shaken and separated.
The aqueous phase was extracted with hexanes (5 × 25 mL). The combined organic extracts were
concentrated in vacuo and the crude mixture was purified by chromatography on a silica gel column
(eluting with 100% hexanes) to afford 1-(2,2-dibromovinyl)-3-methoxybenzene (2.88 g, 9.9 mmol, 99%):
1H-NMR (400 MHz, CDCl3) δ 7.46 (bs, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.12 (tm, J = 1.9 Hz, 1H), 7.09 (ddt,
J = 7.7, 1.4, 0.8 Hz, 1H), 6.89 (ddd, J = 8.3, 2.6, 0.8 Hz, 1H), 3.82 (s, 3H) ppm. The compound was in
complete agreement with previously reported data [26,27].
A one-necked round bottom flask was charged with a solution of 1-(2,2-dibromovinyl)-
3-methoxybenzene (2.88 g, 9.9 mmol, 1 eq.) in anhydrous tetrahydrofuran (30 mL) and the resulting
pale yellow solution was allowed to cool to −78 ◦C (dry ice/acetone bath) and the mixture was then
treated with n-butyllithium (15 mL, 21.9 mmol, 2.2 eq., c = 1.47 M) dropwise over 13 min during which
time mixture turned brighter yellow, red and finally purple. The mixture was allowed to further stir at
−78 ◦C over 1.5 h. After this time the cooling bath was removed and mixture allowed to stir at ambient
temperature for 1.8 h. After this time brown homogeneous mixture was quenched with saturated
aq. NH4Cl (20 mL) and the mixture was further diluted with H2O (20 mL) and Et2O (50 mL) and the
two layers were well shaken and separated. The aqueous phase was extracted with Et2O (2 × 50 mL).
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The combined organic extracts were washed with brine (40 mL), dried (Na2SO4) and concentrated in
vacuo to give dark yellow oily residue. The residue was purified by chromatography on a silica gel
column (eluting with 100% hexanes) to afford the title compound (884 mg, 6.7 mmol, 67%): 1H-NMR
(400 MHz, CDCl3) δ 7.23 (ddm, J = 7.5 Hz, 1H), 7.09 (ddd, J = 7.6, 1.2 Hz, 1H), 7.02 (dd, J = 2.6, 1.4 Hz,
1H), 6.91 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 3.80 (s, 3H), 3.06 (s, 1H) ppm. The compound was in complete
agreement with previously reported data [26,28].
2-((3-Methoxyphenyl)ethynyl)-6-methylpyridine (2). A two-necked round bottom flask was evacuated,
backfilled with an inert atmosphere and then charged with anhydrous N,N′-dimethylformamide (7 mL)
and 2-bromo-6-methylpyridine (0.66 mL, 998 mg, 5.8 mmol, 1 eq., d = 1.512) was added and colourless
solution was treated with tetrakis(triphenylphosphine)palladium(0) (201 mg, 0.174 mmol, 0.3 eq.) in
one portion and the resulting yellow heterogeneous mixture was allowed to stir at ambient temperature
over 13 min. After this time triethylamine (2.42 mL, 1.76 g, 17.4 mmol, 3 eq., d = 0.726) was added and
mixture further allowed to stir for 14 min. During this time mixture became completely homogeneous
and pale yellow and it was further treated with copper(I)iodide (110 mg, 0.58 mmol, 0.1 eq.) and then
a solution of m-ethynylanisole (766 mg, 5.80 mmol, 1 eq.) in anhydrous N,N′-dimethylformamide
(7 mL) was added and the resulting green-brown mixture was allowed to stir at ambient temperature
over 47.5 h. After this time the mixture was quenched with saturated aq NH4Cl (100 mL) and then
diluted with EtOAc (150 mL) and the two layers were well shaken and separated. The aqueous
phase was extracted with EtOAc (2 × 150 mL). The combined organic extracts were washed with
H2O (3 × 110 mL), brine (120 mL), dried (Na2SO4) and concentrated in vacuo. The crude reaction
mixture was purified by chromatography on a silica gel column (eluting with a gradient 10% to 20%
EtOAc/pentane) to afford the title compound (1.2 g, 5.4 mmol, 93%): 1H-NMR (400 MHz, CDCl3)
δ 7.57 (dd, J = 7.7 Hz, 1H), 7.36 (dm, J = 7.6 Hz, 1H), 7.26 (dd, J = 7.3 Hz, 1H), 7.20 (ddd, J = 7.6,
1.3 Hz, 1H, some roofing observed), 7.14 (dd, J = 2.6, 1.4 Hz, 1H), 7.11 (dm, J = 7.8 Hz, 1H), 6.92 (ddd,
J = 8.1, 2.6, 1.1 Hz, 1H), 3.82 (s, 3H), 2.59 (s, 3H) ppm. The compound was in complete agreement with
previously published data [14].
2-((3-Methoxyphenyl)ethynyl)-6-methylpyridine hydrochloride salt (2·HCl). A one-necked round bottom
flask was charged with 2-((3-methoxyphenyl)ethynyl)-6-methylpyridine (108 mg, 0.48 mmol, 1 eq.)
and ethanol (1 mL) was added and pale yellow solution was allowed to cool to 0 ◦C (the ice bath) and
it was then treated with ethanolic solution of HCl dopwise over 1 min and the resulting bright yellow
solution was allowed to stir at 0 ◦C for 1 h. After this time the cooling bath was removed and bright
yellow mixture was concentrated in vacuo to give crude mixture which was further recrystallized from
iPrOH:EtOH 2:1 to afford the title compound (110 mg, 0.42 mmol, 87%): 1H-NMR (400 MHz, CDCl3) δ
8.12 (dd, J = 7.9 Hz, 1H), 7.66 (dm, J = 7.85 Hz, 1H), 7.49–7.45 (m, 2H), 7.43 (ddd, J = 7.5, 1.1 Hz, 1H,
some roofing observed), 7.31 (ddm, J = 8.2 Hz, 1H), 7.02 (ddd, J = 8.4, 2.6, 1.0 Hz, 1H), 3.87 (s, 3H), 3.05
(s, 3H) ppm. The compound was in complete agreement with previously published data [14].
4-Bromo-2-methylthiazole (8). A flame dried flask was charged with 2,4-dibromothiazole (500 mg,
2.1 mmol, 1 eq.) and anhydrous diethyl ether was added (12 mL) and the colourless solution was
allowed to cool to −78 ◦C (dry ice/acetone bath) and it was then treated with n-butyl lithium (1.6 mL,
2.3 mmol, 1.1 eq., c = 1.47 M) dropwise over 1 min. The mixture turned pale yellow and it was allowed
to stir at−78 ◦C over 79 min. After this time the mixture a solution of dimethyl sulfate (0.6 mL, 779 mg,
6.2 mmol, 3 eq., d = 1.33) in anhydrous diethyl ether (0.5 mL) was added dropwise over 4 min and the
resulting mixture allowed to stir at −78 ◦C over 4 h and then warm to ambient temperature and stir
under N2 over 15 h. After this time the crude mixture (red in colour) was quenched with saturated
NaHCO3 (5 mL) and then diluted with H2O (8 mL) and EtOAc (20 mL). The two layers were well
shaken and separated and the aqueous phase was extracted with EtOAc (2 × 20 mL). The combined
organic extracts were washed brine (20 mL), dried (Na2SO4) and concentrated in vacuo to give crude
mixture. The crude mixture was purified by chromatography on a silica gel column (eluting with 10%
EtOAc/pentane) to give the title compound (194.3 mg, 1.09 mmol, 53%): 1H NMR (400 MHz, CDCl3) δ
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7.06 (s, 1H), 2.73 (s, 3H) ppm. The compound was in complete agreement with previously published
data [29].
3-((Trimethylsilyl)ethynyl)pyridine (17). A one-necked round bottom flask was charged with
3-ethynyl-pyridine (150 mg, 1.46 mmol, 1 eq.), anhydrous tetrahydrofuran (4.8 mL) was added and
pale brown solution was allowed to cool to −78 ◦C (dry ice/acetone bath) and it was then treated with
a solution of lithium hexamethyldisilazide (2 mL, 1.9 mmol, 1.3 eq., c = 1 M) dropwise over 2 min
during which time the mixture turned orange and it was allowed to stir at −78 ◦C for 1 h. After this
time orange mixture was treated with trimethylchlorosilane (0.27 mL, 238 mg, 2.19 mmol, 1.5 eq.,
d = 0.856) and the mixture was allowed to slowly warm to ambient temperature and further stir over
17.5 h. After this time the crude mixture was quenched with H2O (10 mL) and then diluted with
Et2O (10 mL) and the two layers were well shaken and separated. The aqueous phase was further
extracted with Et2O (2 × 10 mL). The combined organic extracts were washed with brine (10 mL),
dried (Na2SO4) and concentrated in vacuo. The crude mixture was purified by chromatography on a
silica gel column (eluting with 5% EtOAc/pentane) to afford the title compound (56.1 mg, 0.32 mmol,
22%): 1H-NMR (400 MHz, CDCl3) δ 8.69 (dd, J = 2.0, 0.7 Hz, 1H), 8.52 (dd, J = 4.9, 1.7 Hz, 1H), 7.74
(ddd, J = 7.8, 1.9 Hz, 1H), 7.23 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 0.26 (s, 9H) ppm. The compound was also
available from commercial sources and the spectral data were in complete agreement.
1-Chloro-4-(trimethylsilyl)but-3-yn-2-one (19). A one-necked round bottom flask was charged with
aluminium trichloride (5.5 g, 42 mmol, 1.3 eq.) and anhydrous dichloromethane (63 mL) was added
and the resulting yellow suspension was allowed to cool to 0 ◦C (the ice bath). The mixture was
then treated with a solution of chloroacetyl chloride (2.6 mL, 3.65 g, 32.3 mmol, 1 eq., d = 1.417) and
bis(trimethylsilyl)acetylene (6.6 mL, 5 g, 29.34 mmol, 0.9 eq., d = 0.752) in anhydrous dichloromethane
(38 mL) dropwise over 50 min during which time mixture turned darker yellow and finally brown and
it was allowed to stir at 0 ◦C over 1 h. The cooling bath was then removed and the stirring continued
at ambient temperature over 65 min. After this time the mixture was allowed to cool to 0 ◦C (the
ice bath) and it was carefully quenched with 1 M aq. HCl (65 mL). The two layers were well shaken
and separated. The aqueous phase was further extracted with CH2Cl2 (2 × 125 mL). The combined
organic extracts were washed with H2O (125 mL), saturated aq. NaHCO3 (125 mL), brine (125 mL),
dried (Na2SO4) and concentrated in vacuo to give brown reside. The crude mixture was purified
via Kugelrorh distillation (temperature: 75 ◦C) at 2 × 10−2 kPa to afford the title compound (4.33 g,
24.8 mmol, 77%): 1H-NMR (400 MHz, CDCl3) δ 4.23 (s, 2H), 0.26 (s, 9H) ppm. The compound was in
complete agreement with previously published data [15].
2-Methyl-4-((trimethylsilyl)ethynyl)thiazole (20). A one-necked round bottom flask was charged
with 1-chloro-4-(trimethylsilyl)-3-butyn-2-one (4.3 g, 24.6 mmol, 1 eq.) and anhydrous
N,N′-dimethylformamide (43 mL) was added and the clear yellow solution was treated with
thioacetamide (2.4 g, 31.8 mmol, 1.3 eq.) in one portion and the resulting yellow homogeneous
mixture was allowed to stir at ambient temperature over 17 h. After this time the crude mixture
was diluted with EtOAc (200 mL) and the organic phase was washed with H2O (3 × 150 mL), brine
(150 mL), dried (Na2SO4) and concentrated in vacuo to give brown oily residue. The crude mixture was
purified by chromatography on a silica gel column (eluting with gradient 2% to 4% EtOAc/hexanes)
to afford the title compound (4.75 g, 24.3 mmol, 99%): 1H-NMR (400 MHz, CDCl3) δ 7.32 (s, 1H),
2.70 (s, 3H), 0.24 (s, 9H) ppm. The compound was in complete agreement with previously published
data [15].
4-Ethynyl-2-methylthiazole (10). A one-necked round bottom flask was charged with 2-methyl-
4-((trimethylsilyl)ethynyl)thiazole (400 mg, 2.05 mmol, 1 eq.) and methanol (0.5 mL) was added
and the red mixture was further treated with a solution of potassium hydroxide (230 mg, 4.1 mmol,
2 eq.) in methanol (4.8 mL) in one portion and the resulting dark brown mixture was allowed to stir
over 3.5 h. After this time the mixture was quenched with H2O (10 mL) and diluted with EtOAc
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(10 mL) and the two layers were well shaken and separated. The aqueous phase was extracted with
EtOAc (3 × 8 mL). The combined organic extracts were washed with brine (8 mL), dried (Na2SO4) and
concentrated in vacuo to give crude mixture. The crude mixture was purified by chromatography on
a silica gel column (eluting with gradient 5% to 10% EtOAc/pentane) to afford the title compound
(172.6 mg, 1.40 mmol, 68%): 1H-NMR (400 MHz, CDCl3) δ 7.37 (s, 1H), 3.09 (s, 1H), 2.71 (s, 3H)
ppm. The compound was also available from commercial sources and the spectral data were in
complete agreement.
2-Methyl-4-(pyridin-3-ylethynyl)thiazole (3). A one-necked round bottom flask was charged with
2-methyl-4-[(trimethylsilyl)ethynyl]-1,3-thiazole (3.84 g, 19.7 mmol, 1 eq.) and 3-bromopyridine
(2.1 mL, 3.42 g, 21.6 mmol, 1.1 eq., d = 1.64) was added in one portion and then 1,2-dimethoxyethane
(50 mL) was added and the resulting brown heterogeneous mixture was treated with triethylamine
(5.5 mL, 3.98 g, 39.4 mmol, 2 eq.) in one portion and the mixture was sparged with N2 and the
flask was allowed to heat (temperature of preheated oil bath: 70 ◦C). Immediately upon heating
tetrakis(triphenylphosphine)palladium (0) (446 mg, 0.39 mmol, 0.02 eq.) was added and sparging
continued for another 14 min. After this time sparging was discontinued and the mixture treated with
a solution of tetrabutylammonium fluoride (25 mL, 25.4 mmol, 1.3 eq., c = 1 M) in tetrahydrofuran
was added via syringe pump (5 mL/h in 20 mL syringe) whilst the mixture was heated over 20 h. The
crude mixture was concentrated in vacuo and the residue dissolved in EtOAc (400 mL) and the organic
phase washed with H2O (200 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo
to give brown oily residue. The crude reaction mixture was purified by chromatography on a silica
gel column (eluting with gradient 30% to 50% EtOAc/hexanes) to give the title compound (2.06 g,
10.3 mmol, 52%). The material was then recrystallized from hot EtOAc layered with cold hexanes
to afford yellow needles (1.32 g, 6.6 mmol, 33%): 1H-NMR (400 MHz, CDCl3) δ 8.79 (bd, J = 1.3 Hz,
1H), 8.57 (dd, J = 4.8, 1.4 Hz, 1H), 7.83 (ddd, J = 7.9, 1.9 Hz, 1H), 7.43 (s, 1H), 7.29 (ddd, J = 7.8, 4.9,
0.8 Hz, 1H), 2.75 (s, 3H) ppm. The compound was in complete agreement with previously published
data [15,17].
2-Methyl-4-(pyridin-3-ylethynyl)thiazole hydrochloride salt (3·HCl). A one-necked round bottom flask
was charged with 2-methyl-4-(pyridin-3-ylethynyl)thiazole (214 mg, 1.07 mmol, 1 eq.) and ethanolic
solution of hydrochloric acid (1.1 mL, 1.07 mmol, 1 eq., c = 1 M) was added but material did not
completely dissolve and additional EtOH (1 mL) was added and the resulting heterogeneous mixture
allowed to stir at ambient temperature over 30 min. After this time the mixture was concentrated in
vacuo and the residue recrystallized from iPrOH to yield the title compound (168.3 mg, 0.71 mmol,
66%): 1H-NMR (400 MHz, CDCl3) δ 8.87 (bs, 1H), 8.74 (bd, J = 5.4 Hz, 1H), 8.46 (bddd, J = 8.1, 1.6 Hz,
1H), 7.92 (bdd, J = 8.0, 1.6 Hz, 1H), 7.63 (s, 1H), 2.77 (s, 3H) ppm. The compound was also available
from commercial sources and the spectral data were in complete agreement.
2-Ethynyl-6-methylpyridine (6). A solution of 2-bromo-6-methylpyridine (700 mg, 4.06 mmol, 1 eq.) in
triethylamine (degassed, 11.7 mL) was at ambient temperature treated with trimethylsilylacetylene
(0.63 mL, 438 mg, 4.47 mmol, 1.1 eq., d = 0.709), copper(I)iodide (76 mg, 0.4 mmol, 0.1 eq.) and
trans-dichlorobis(triphenylphospine)palladium (280 mg, 0.4 mmol, 0.1 eq.). The resulting solution was
allowed to stir at ambient temperature over 17 h. After this time the crude mixture was quenched with
H2O (8 mL) and further extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried
(Na2SO4) and concentrated in vacuo and the crude mixture was purified by chromatography on a silica
gel column (eluting with 5% Et2O/pentane) to afford 2-methyl-6-((trimethylsilyl)-ethynyl)pyridine
(537 mg, 2.84 mmol, 70%): 1H-NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 7.7 Hz, 1H), 7.28 (dm,
J = 7.9 Hz, 1H), 7.09 (dm, J = 7.6 Hz, 1H), 2.55 (s, 3H), 0.26 (s, 9H) ppm. The compound was in
complete agreement with previously published data [14].
A yellow solution of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine (226 mg, 1.19 mmol, 1 eq.) in
methanol (0.3 mL) was treated with the solution of potassium hydroxide (134 mg, 2.39 mmol, 2 eq.) in
methanol (2.5 mL) and the resulting colourless solution was allowed to stir at ambient temperature
Pharmaceuticals 2018, 11, 24 11 of 13
over 2.5 h. After this time the crude mixture was quenched with H2O (6 mL) and diluted with EtOAc
(5 mL) and the two layers were well shaken and separated. The aqueous phase was extracted with
EtOAc (3 × 5 mL). The combined organic extracts were washed with brine (3 mL), dried (Na2SO4)
and concentrated in vacuo. The crude reaction mixture was purified by chromatography on a silica
gel column (eluting with gradient 5% to 10% EtOAc/pentane) to afford the title compound (84 mg,
0.72 mmol, 60%): 1H-NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 7.8 Hz, 1H), 7.29 (dm, J = 7.8 Hz, 1H), 7.13
(dm, J = 7.8 Hz, 1H), 3.12 (s, 1H), 2.55 (s, 3H) ppm. The compound was in complete agreement with
previously published data [14].
4. Conclusions
In conclusion, employing Sonogashira cross-coupling reaction, two mGlu5 antagonists MMPEP
(2) and MTEP (3) were prepared by an improved synthetic method in 62% and 40% overall yields,
respectively. Computationally calculated HOMO energies for the reacting partners suggested that
product formation is controlled by both reacting partners, the halide and the alkyne. Our findings
revealed that synthetically meaningful yields were achieved when HOMO energy of the halide was
lower than that of the alkyne. Furthermore, our results point to possibility of other high-lying molecular
orbitals which may be more critical predictors of reactivity. While not all halide-alkyne combinations
were attempted, the experimental data of our study support the computationally obtained conclusions,
thus furthering our understanding of the requirements for the successful Sonogashira cross-coupling.
Supplementary Materials: The following are available online at www.mdpi.com/1424-8247/11/1/24/
s1, detailed experimental procedure and characterization data as well as Cartesian co-ordinates for all
reported compounds.
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